You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 269 No. 1, January 6, 1993 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Commentary
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

AIDS-Associated Primary Central Nervous System Lymphoma

Giorgio Galetto, MD; Alexandar Levine, MD

JAMA. 1993;269(1):92-93.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

A CLINICAL and scientific impasse in the area of primary central nervous system (P-CNS) lymphoma related to the acquired immunodeficiency syndrome (AIDS) has provoked this commentary from the Oncology Committee of the AIDS Clinical Trials Group (ACTG), a national cooperative group for the treatment of human immunodeficiency virus (HIV) infection and its associated illnesses. We believe that progress in this area has been impeded because of two unwarranted assumptions: first, the fear of contagion, which has prevented some neurosurgeons from obtaining biopsy specimens from HIV-infected patients with intracerebral mass lesions1; and second, the belief that treatment would be ineffective, which has prevented many primary practitioners from referring such patients, and many oncologists from treating them, even in the setting of prospective protocols. These attitudes have impeded attempts to obtain primary tissues from which to make appropriate diagnoses, or to develop improved therapeutic strategies, serving to fulfill existing negative expectations. . . . [Full Text PDF of this Article]


Author Affiliations

for the Oncology Core Committee, AIDS Clinical Trials Group National Institute of Allergy and Infectious Diseases

From the Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, Md (Dr Galetto); and University of Southern California School of Medicine, Los Angeles (Dr Levine).


Footnotes

Reprint requests to University of Southern California School of Medicine, 1441 Eastlake Ave, Los Angeles, CA 90033 (Dr Levine).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1993 American Medical Association. All Rights Reserved.